Oncosil Medical (OSL) Company presentation summary

Operational achievements

• Expanded global presence with exclusive distribution agreements in GCC, Egypt, and Nordics.

• G-BA approval for a fully funded clinical trial in Germany, with OncoSil device reimbursement.

• EU and UK conformity assessment approvals remove post-market restrictions, accelerating market access.

• First OncoSil treatment at a leading Italian cancer center strengthens EU footprint.

• TRIPP-FFX and PANCOSIL clinical trials both exceed 75% recruitment.

Financial highlights

• $0.402 million revenue from commercial sales in the six months to 31 Dec 2024.

• $8.46 million cash and cash equivalents as of 31 Dec 2024.

• $10.93 million raised, strengthening cash position and balance sheet.

• $1.05 million R&D tax rebate received in January 2025.

Regulatory and market access milestones

• G-BA approval enables a fully funded, revenue-positive CED trial in Germany.

• InEK authorizes 120 German hospitals to negotiate funding for the device, a 43% increase over 2024.

• MDR EU certification from BSI removes post-market restrictions and streamlines onboarding.

• Up to €2 million in cost savings over three years from reduced ethics approval and recruitment costs.

• Opportunity to resubmit marketing authorization to TGA by Q2.